Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Can't Please Everybody: FDA's "Brief Summary" Redesign May Require Flexibility

This article was originally published in The Pink Sheet Daily

Executive Summary

Drug Facts Box format scored well in a broad study, but researchers found it may not be the best format for everyone.
Advertisement

Related Content

Should FDA Make Patients Care About A Problem If They Don’t Already?
Risk Communication Panel To Continue Discussion Of Uncertainty Messaging
Rx Safety Communication In Face Of Uncertainty, Multiple Risks, To Be Examined By FDA Panel
“Drug Facts” Box Not Ready For Prime Time, FDA Advisory Cmte. Says
Valeant Continues Its Expansion With Acquisition Of PharmaSwiss
Valeant Continues Its Expansion With Acquisition Of PharmaSwiss
FDA May Allow "Qualitative" Labels For Data In DTC Ads
“Brief Summary” Format Changes: FDA Gets Proof of Principle In First Study
“Brief Summary” Format Changes: FDA Gets Proof of Principle In First Study

Topics

Advertisement
UsernamePublicRestriction

Register

PS072398

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel